Bristol Myers Squibb Co. has prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety through a linker reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.
Nanjing Gentai Pharmaceutical Technology Co. Ltd. has divulged dual inhibitors of poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) and serine/threonine-protein kinase ULK1 reported to be useful for the treatment of cancer.
Muna Therapeutics ApS has patented triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes and more.
Sec61 is a critical component of the protein translocation machinery that mediates the entry of most secreted and transmembrane proteins into the endoplasmic reticulum. Sec61 has been proposed as a promising therapeutic target to block the expression of protumorigenic factors, with the potential to modulate both tumor-intrinsic and -extrinsic factors.
Endometrial cancer is the second most prevalent gynecological malignancy. Current standard treatments for endometrial cancer typically include a combination of surgery, radiation therapy and, in some cases, chemotherapy or hormonal therapy, depending on the tumor stage and molecular characteristics. However, the outcomes for metastatic and recurrent cases remain poor.
Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of HNSCC that is not associated with human papilloma virus infection, the natural killer cells that could fight HNSCC tumors are inhibited within the tumor microenvironment, in part because of the hypoxic conditions.
In the search for effective and safe Kv7 activators, a collaboration spanning Belgium, Germany and Italy has identified JNJ-37822681 as a promising lead.
GSK plc scientists have presented findings from studies on the therapeutic potential of GSK-5862611, an anti-Sortilin antibody, in addressing neurodegenerative disease mechanisms linked to the TDP43 G298S mutation.
RSS
